Skip to content

The effect of dexmedetomidine on awakening quality and cognitive function in patients with mild cognitive impairment

The effect of dexmedetomidine on awakening quality and cognitive function in patients with mild cognitive impairment

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095570
Enrollment
Unknown
Registered
2025-01-09
Start date
2025-03-15
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative cognitive dysfunction, delirium, etc., symptoms: confusion, babbling, irritability.

Interventions

Dexmedetomidine group:administering dexmedetomidine 0.6 µg/kg by pump 10 min before chest closure
Control group :In the last 10 min before closing the chest, the corresponding dose of normal saline was infused.

Sponsors

Cangzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 75 Years

Inclusion criteria

Inclusion criteria: One hundred patients with mild cognitive impairment who underwent thoracoscopic lobectomy under general anesthesia in our hospital were selected, aged 65-5 years, with a body mass index of 18.5-23.9 kg/m2, and ASA I/II. Before the operation, had reduced memory and forgetfulness, with MoCA scores of 15-24 and MMSE scores of =27 (17-27 illiterates, 20-27 for those with =6 years of education, and 24-27 for those with >6 years education).

Exclusion criteria

Exclusion criteria: Preoperative neurodegenerative diseases that affect cognitive function (eg, vascular dementia), severe hepatic and renal insufficiency, cardiopulmonary insufficiency, history of autoimmune diseases, recent use of sedatives, antidepressants, or immunosuppressive drugs, history of head injury and alcohol abuse, visual and hearing impairment.

Design outcomes

Primary

MeasureTime frame
Quality of awakening: Agitation, Sedation, Shivering, Urethral catheter irritation;Postoperative cognitive function;Apolipoprotein J, IL-1B, TNF-a inflammation-related indicators;

Secondary

MeasureTime frame
Operation time, anesthesia time, sufentanil citrate usage, bleeding volume, fluid infusion volume;

Countries

china

Contacts

Public Contactwanglei

Cangzhou Central Hospital

1058089565@qq.com+86 157 3170 1656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026